Imaging in Ganglioneuroma and Ganglioneuroblastoma
No Results
No Results
processing….
Ganglioneuromas and ganglioneuroblastomas are tumors of the sympathetic nervous system that originate from neural crest sympathogonia, which are completely undifferentiated cells of the sympathetic nervous system. Along with neuroblastomas, ganglioneuromas and ganglioneuroblastomas are collectively known as neuroblastic or neurogenic tumors. [1, 2]
Most frequently occurring in the abdomen, these tumors can grow wherever sympathetic nervous tissue is found. Common locations for ganglioneuromas and ganglioneuroblastomas include the adrenal gland, paraspinal retroperitoneum (sympathetic ganglia), posterior mediastinum, head, and neck; it is uncommon to find them in the urinary bladder, bowel wall, abdominal wall, and gallbladder. See the images below.
Magnetic resonance imaging (MRI) and computed tomography (CT) scanning are the preferred methods for imaging ganglioneuromas and ganglioneuroblastomas. [3, 4, 5] MRI is the modality of choice for evaluating the extension of spinal tumors. [6, 7]
CT scanning is the imaging modality that is most commonly used to evaluate neuroblastic tumors. It has proven to be the superior imaging technique when identifying tumor size, organ of origin, tissue invasion, vascular encasement, adenopathy, and calcifications. Newly diagnosed cases are evaluated with standard chest, abdominal, and pelvic CT scans. [6]
In general, neuroblastic or neurogenic tumors appear radiologically as well-circumscribed, smooth or lobulated masses that may contain calcifications. The benign (ganglioneuromas) and malignant (ganglioneuroblastomas) forms of these tumors are virtually identical radiologically. The only differentiating factor is the possibility of distant metastases with malignant ganglioneuroblastomas.
The International Neuroblastoma Staging System (INSS) was developed to stage these tumors by using clinical, radiologic, and surgical data (see Neuroblastoma for more detailed information regarding the INSS). [6]
Complete surgical resection of ganglioneuromas is important, because it allows for good tissue sampling and a thorough pathology examination of the specimen to ensure a correct diagnosis of ganglioneuroma. In rare cases, these tumors recur; therefore, radiologic examination is an important tool for the proper localization and characterization of primary and recurrent tumors. These tumors are identified on radiologic examination on the basis of their location, shape, and internal structure; however, the diagnosis of ganglioneuroma cannot be based on radiologic findings alone. [8]
Ganglioneuromas are typically discovered on a routine radiograph. However, on radiologic examination, all neuroblastic tumors (ie, ganglioneuroblastomas, ganglioneuromas, and neuroblastomas) look similar. The main difference is that ganglioneuroblastomas and neuroblastomas can possibility metastasize.
These tumors have highly variable radiologic appearances and growth behaviors that are reflective of their variable locations. Conventional radiographs show a retroperitoneal, posterior mediastinal, pelvis, or neck mass (see the following images). Up to 30% of these tumors may show calcifications. Rib and vertebral foraminal erosions, increased intercostal spaces, and vertebral body pedicle erosions may be seen with both retroperitoneal and posterior mediastinal tumors. Hepatomegaly, periostitis, widened cranial sutures, focal bone lucencies, focal bone sclerosis, and lucent submetaphyseal zones may indicate metastatic disease. [6]
CT scanning is the imaging modality that is most commonly used to evaluate neuroblastic tumors. It has proven to be the superior imaging technique when identifying tumor size, organ of origin, tissue invasion, vascular encasement, adenopathy, and calcifications. Newly diagnosed cases are evaluated with standard chest, abdominal, and pelvic CT scans. [6]
Retroperitoneal and adrenal ganglioneuromas appear well-defined. Their shape ranges from round to lobulated, they show discrete and punctate calcifications in 42-60% of cases, and they tend to grow around major blood vessels. Ganglioneuromas do not compress these blood vessels, and blood flow remains normal. [1]
Nonenhanced CT scanning reveals a homogeneous mass with less attenuation than muscle. Ichikawa et al described a delayed heterogeneous uptake of contrast in a ganglioneuroma. [9] The reason for this type of uptake is that these tumors take longer to accumulate contrast material in the extracellular space. This delay is directly proportional to the amount of myxoid stroma in the tumor.
Ganglioneuroblastomas have a variable appearance on CT scans and can be cystic or solid. [1] Abdominal and pelvic tumors are mostly heterogeneous and large; smaller tumors may appear homogeneous. See the image below.
Areas of bleeding and necrosis may be as large as 4 cm and appear to be of lower attenuation. These tumors can grow around blood vessels but rarely invade them. Vessel compression, however, is a realistic possibility. If compression of renal vasculature occurs, hypertension can result. [6] Other vessels at risk include the splenic vein, inferior vena cava, aorta, celiac artery, and superior mesenteric artery (SMA).
Any metastasis to the liver or lung and adenopathy can also be identified on CT scans. Liver metastases appear as diffuse infiltration (in infants) and as focal areas of low enhancement. Metastatic disease of the lung can appear either as well-defined nodules or as larger areas of tissue consolidation. Although exceedingly rare, brain metastases do occur and have a variable appearance, ranging from hemorrhagic to cystic with rim-enhancement to a solid mass.
Intracranial dural involvement is a more common occurrence and can be seen as meningeal masses and meningeal enhancement. These metastatic tumors may be large enough to produce mass effect on the brain and cranium (suture widening). Metastatic involvement of the sphenoid bone that extends into the orbits produces a red and blue discoloration of the orbits that can be misinterpreted as physical abuse. [10]
MRI is a multiplanar imaging technique that creates images with better tissue discrimination than CT scanning. This makes MRI more effective at evaluating organs of origin, regional invasion, and intraspinal tumoral extension. Any patient with a paraspinal tumor should undergo an MRI to evaluate possible tumoral invasion of the epidural space. In these cases, coronal, sagittal, and axial views can demonstrate spinal cord and nerve root displacement as well as superior and inferior tumor growth. [7] See the following images.
MRI is also useful for imaging bone marrow; the lesions appear hypointense on T1-weighted images and hyperintense on T2-weighted images. In addition, MRI can be used to detect hepatic metastases in infants with stage 4S disease, which can be missed on CT scanning because of its appearance as a uniform increase in liver attenuation. These lesions appear hyperintense on T2-weighted MRIs. [6, 11]
Ganglioneuromas appear homogeneous on MRIs and have a relatively intermediate signal intensity on all sequences. [12] Tumors with intermediate to high signal intensity on T2-weighted images have a higher degree of cellularity and more collagen. These tumors will have a small myxoid component. Markedly-high T2 intensity, on the other hand, signifies a high myxoid stroma component and low cellularity and collagen amounts. [1]
Ganglioneuromas have characteristic curvilinear bands of low signal-intensity on T2-weighted images that impart a whorled pattern to the tumor. These bands are composed of collagen fibers and intertwined bundles of Schwann cells. The capsule surrounding the tumor appears as a low-density ring on both T1- and T2-weighted images.
Contrast enhancement with MRI is similar to contract enhancement with CT imaging. Early contrast enhancement occurs in areas of relatively high vascularity with high capillary permeability. However, delayed enhancement results when diffusion of the enhancing material into the extravascular space is slowed or impeded. [13] Therefore, fibrous tissues show slow or late enhancement. These tumors enhance gradually, with final enhancement ranging from none to marked. MRI is the modality of choice for evaluating the extension of spinal tumors. [6]
Ganglioneuroblastomas appear heterogeneous on MRIs, with variable enhancement and low signal-intensity on T1-weighted images and high signal-intensity on T2-weighted images. [14] Tumor calcifications are more difficult to appreciate on MRIs than on CT scans; on MRIs, they appear as signal voids. Areas of hemorrhage have a high T1 signal-intensity and cystic areas have a high T2 signal-intensity. [6] Ganglioneuroblastomas, like neuroblastomas and other malignant tumors, have an enhancing pattern of early enhancement followed by a partial washout; early enhancement is indicative of high vascularity. [13]
The differential diagnosis of ganglioneuroma and ganglioneuroblastoma includes neuroblastoma, adrenal adenoma, adrenal carcinoma, neurofibroma, schwannoma, and pheochromocytoma. Ganglioneuromas can be differentiated from more aggressive neuroblastomas and ganglioneuroblastomas by their regular contours and lack of tissue invasion and vessel encasing, their occurrence in older patients, and their discrete, punctate calcifications on CT scans. Neuroblastomas and ganglioneuroblastomas tend to have amorphous or coarse calcifications. In addition, ganglioneuromas rarely metastasize, whereas neuroblastomas and ganglioneuroblastomas can metastasize to bone, skin, and other organs. [13]
It is more difficult to differentiate ganglioneuromas from schwannomas or neurofibromas. In general, schwannomas and neurofibromas are round and can cause bone erosion and destruction. Most ganglioneuromas are flat and elongated and they normally do not affect bone. Schwannomas may demonstrate cystic degeneration that does not occur in ganglioneuromas. Neurofibromas do not have a capsule; the presence of one in a patient would point to a ganglioneuroma diagnosis. [13]
Adrenal disease can be differentiated from neuroblastic tumors by its unique enhancing patterns. Adrenal adenomas enhance and wash out early, whereas pheochromocytomas and adrenocortical carcinomas strongly enhance early but wash out at a slower rate. Adrenal carcinomas invade vascular structures in more than 50% of the cases. [13]
Additional MRIs of these tumors are provided below.
Ultrasonography of a ganglioneuroma would show a homogeneous, hypoechoic, well-circumscribed mass. [11]
Ganglioneuroblastomas show heterogeneic echogenicity, with areas of hemorrhage and necrosis appearing anechogeneic. Calcifications appear as either focal or diffuse areas of increased echogenicity with variable appearance of shadowing. Ultrasonography has proven to be useful in evaluating other organs for metastasis and for determining blood flow in blood vessels surrounded by tumor. [6]
In cases of ganglioneuroblastoma, scintigraphy is not only useful for identifying the primary tumor, but it is also useful for monitoring the pattern of metastatic spread. Primary and metastatic tumors take up catecholamine and somatostatin analogs.
Iodine-tagged metaiodobenzylguanidine (MIBG), a catecholamine analog, is used to identify catecholamine-producing tumors such as ganglioneuroblastoma, ganglioneuroma, neuroblastoma, pheochromocytoma, carcinoid tumor, and medullary thyroid cancer. [15, 16, 17, 18]
Technetium-99m (99m Tc) testing is an initial study done in all patients with diagnosed ganglioneuroblastoma to determine the amount of metastatic disease present; however, as many as 75% of primary tumors also show uptake. This method is preferred for the examination of bone metastases, as cortical and marrow lesions are difficult to discriminate (as they are with MIBG studies). Metastases appear as areas of higher uptake, and they include areas such as the lung and liver. The amount of99m Tc uptake is, purportedly, directly related to calcium metabolism of the tumor cells.
Ganglioneuromas can accumulate MIBG in a fashion similar to ganglioneuroblastomas; tumors that uptake MIBG are catecholamine-producing tumors. [15, 16, 17, 18] Although 90-95% of ganglioneuroblastomas produce catecholamines, only approximately 70% take up MIBG. Therefore, negative results do not mean there is no disease. Despite this limitation, MIBG scintigraphy has an 88% sensitivity and a 99% specificity for tumors containing sympathetic tissue, such as ganglioneuroblastomas, ganglioneuromas, neuroblastomas, pheochromocytomas, and carcinoids. The disadvantage is that there is no way to discriminate the type of tumor in which the uptake occurs. When bone is affected, this method also makes staging difficult, because it does not distinguish cortical involvement from marrow involvement.
Unfortunately, up to 50% of recurrent tumors do not take up MIBG. This makes MIBG scintigraphy a poor method of post-therapeutic monitoring for recurrences. Somatostatin-analog testing is also used to evaluate neuroblastic tumors, but it is not as specific as an MIBG study. [6, 19]
Rha SE, Byun JY, Jung SE, et al. Neurogenic tumors in the abdomen: tumor types and imaging characteristics. Radiographics. 2003 Jan-Feb. 23(1):29-43.
De Bernardi B, Gambini C, Haupt R, Granata C, Rizzo A, Conte M, et al. Retrospective study of childhood ganglioneuroma. J Clin Oncol. 2008 Apr 1. 26(10):1710-6. [Medline].
Rabah R, Weber R, Serhatkulu GK, Cao A, Dai H, Pandya A. Diagnosis of neuroblastoma and ganglioneuroma using Raman spectroscopy. J Pediatr Surg. 2008 Jan. 43(1):171-6. [Medline].
Guo YK, Yang ZG, Li Y, Deng YP, Ma ES, Min PQ, et al. Uncommon adrenal masses: CT and MRI features with histopathologic correlation. Eur J Radiol. 2007 Jun. 62(3):359-70. [Medline].
Stutterheim J, Gerritsen A, Zappeij-Kannegieter L, Yalcin B, Dee R, van Noesel MM, et al. Detecting Minimal Residual Disease in Neuroblastoma: the Superiority of a Panel of Real-Time Quantitative PCR Markers. Clin Chem. 2009 May 21. [Medline].
Lonergan GJ, Schwab CM, Suarez ES, Carlson CL. Neuroblastoma, ganglioneuroblastoma, and ganglioneuroma: radiologic-pathologic correlation. Radiographics. 2002 Jul-Aug. 22(4):911-34. [Medline].
Yılmaz B, Toktaş ZO, Akakın A, Demir MK, Yapıcıer O, Konya D. Lumbar Spinal Immature Ganglioneuroma with Conus Medullaris Invasion: Case Report. Pediatr Neurosurg. 2015 Oct 14. [Medline].
Lacreuse I, Valla JS, de Lagausie P, Varlet F, Héloury Y, Temporal G, et al. Thoracoscopic resection of neurogenic tumors in children. J Pediatr Surg. 2007 Oct. 42(10):1725-8. [Medline].
Ichikawa T, Ohtomo K, Araki T, et al. Ganglioneuroma: computed tomography and magnetic resonance features. Br J Radiol. 1996 Feb. 69(818):114-21. [Medline].
Abramson SJ. Adrenal neoplasms in children. Radiol Clin North Am. 1997 Nov. 35(6):1415-53. [Medline].
Benz-Bohm G, Hero B, Gossmann A, Simon T, Körber F, Berthold F. Focal nodular hyperplasia of the liver in longterm survivors of neuroblastoma How much diagnostic imaging is necessary?. Eur J Radiol. 2009 Apr 13. [Medline].
Tanaka O, Kiryu T, Hirose Y, Iwata H, Hoshi H. Neurogenic tumors of the mediastinum and chest wall: MR imaging appearance. J Thorac Imaging. 2005 Nov. 20(4):316-20. [Medline].
Zhang Y, Nishimura H, Kato S, et al. MRI of ganglioneuroma: histologic correlation study. J Comput Assist Tomogr. 2001 Jul-Aug. 25(4):617-23. [Medline].
Gasparetto EL, Rosemberg S, Matushita H, da Costa Leite C. Ganglioneuroblastoma of the cerebellum: neuroimaging and pathological features of a case. Arq Neuropsiquiatr. 2007 Jun. 65(2A):338-40. [Medline].
Ambros PF, Ambros IM, Brodeur GM, Haber M, Khan J, Nakagawara A, et al. International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee. Br J Cancer. 2009 May 5. 100(9):1471-82. [Medline].
Boubaker A, Bischof Delaloye A. MIBG scintigraphy for the diagnosis and follow-up of children with neuroblastoma. Q J Nucl Med Mol Imaging. 2008 Dec. 52(4):388-402. [Medline].
Vik TA, Pfluger T, Kadota R, Castel V, Tulchinsky M, Farto JC, et al. (123)I-mIBG scintigraphy in patients with known or suspected neuroblastoma: Results from a prospective multicenter trial. Pediatr Blood Cancer. 2009 Jul. 52(7):784-90. [Medline].
Taggart D, Dubois S, Matthay KK. Radiolabeled metaiodobenzylguanidine for imaging and therapy of neuroblastoma. Q J Nucl Med Mol Imaging. 2008 Dec. 52(4):403-18. [Medline].
Fendler WP, Melzer HI, Walz C, von Schweinitz D, Coppenrath E, Schmid I, et al. High ¹²³I-MIBG uptake in neuroblastic tumours indicates unfavourable histopathology. Eur J Nucl Med Mol Imaging. 2013 Oct. 40 (11):1701-10. [Medline].
Shin JH, Lee HK, Khang SK, et al. Neuronal tumors of the central nervous system: radiologic findings and pathologic correlation. Radiographics. 2002 Sep-Oct. 22(5):1177-89. [Medline].
Andrzej R Jedynak, MD, MS Clinical Assistant Professor, Department of Radiology, State University of New York Downstate Medical Center
Andrzej R Jedynak, MD, MS is a member of the following medical societies: American College of Radiology, American Medical Association, Radiological Society of North America
Disclosure: Nothing to disclose.
Robert A Schwartz, MD, MPH Professor and Head of Dermatology, Professor of Pathology, Pediatrics, Medicine, and Preventive Medicine and Community Health, Rutgers New Jersey Medical School; Visiting Professor, Rutgers University School of Public Affairs and Administration
Robert A Schwartz, MD, MPH is a member of the following medical societies: Alpha Omega Alpha, New York Academy of Medicine, American Academy of Dermatology, American College of Physicians, Sigma Xi
Disclosure: Nothing to disclose.
Bernard D Coombs, MB, ChB, PhD Consulting Staff, Department of Specialist Rehabilitation Services, Hutt Valley District Health Board, New Zealand
Disclosure: Nothing to disclose.
C Douglas Phillips, MD, FACR Director of Head and Neck Imaging, Division of Neuroradiology, New York-Presbyterian Hospital; Professor of Radiology, Weill Cornell Medical College
C Douglas Phillips, MD, FACR is a member of the following medical societies: American College of Radiology, American Medical Association, American Society of Head and Neck Radiology, American Society of Neuroradiology, Association of University Radiologists, Radiological Society of North America
Disclosure: Nothing to disclose.
L Gill Naul, MD Professor and Head, Department of Radiology, Texas A&M University College of Medicine; Chair, Department of Radiology, Baylor Scott and White Healthcare, Central Division
L Gill Naul, MD is a member of the following medical societies: American College of Radiology, American Medical Association, American Roentgen Ray Society, Radiological Society of North America
Disclosure: Nothing to disclose.
Lucien M Levy, MD, PhD
Lucien M Levy, MD, PhD is a member of the following medical societies: American Cancer Society, American College of Radiology, American Heart Association, American Medical Association, American Roentgen Ray Society, American Society of Neuroradiology, Radiological Society of North America
Disclosure: Nothing to disclose.
Yaron Lebovitz, MD Assistant Professor of Radiology, University of Medicine and Dentistry of New Jersey; Consulting Staff, Department of Radiology, Section of Neuroradiology, University Hospital
Disclosure: Nothing to disclose.
Imaging in Ganglioneuroma and Ganglioneuroblastoma
Research & References of Imaging in Ganglioneuroma and Ganglioneuroblastoma|A&C Accounting And Tax Services
Source
0 Comments